Top

Published in:

01-06-2014 | Review Article

Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin

Authors: Matthew Mei, Sandra Thomas, Robert Chen

Published in: BioDrugs | Issue 3/2014

Abstract

Brentuximab vedotin (Adcetris, Seattle Genetics) is an antibody–drug conjugate (ADC) that joins an anti-CD 30 monoclonal antibody with the anti-tubulin agent monomethyl auristatin E via a dipeptide linker. It has demonstrated significant activity in CD 30-positive lymphomas and is currently approved by the US FDA for treatment of Hodgkin lymphoma that has relapsed following autologous stem-cell transplantation, or after two lines of chemotherapy in non-transplant candidates. Brentuximab vedotin has also been approved for the treatment of relapsed anaplastic large-cell lymphoma after front-line chemotherapy. We briefly review the biology of Hodgkin lymphoma, with a focus on the pathogenic role of CD 30 as well as the development of CD 30-targeted therapy. We also discuss both the current role of brentuximab vedotin in the management of relapsed and refractory Hodgkin lymphoma and the likely future developments for this agent.

Kuppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2009;9(1):15–27. doi:10.1038/nrc2542.PubMedCrossRef

Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17(3):776–83.PubMed

Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, et al. Reed–Sternberg cell genome expression supports a B-cell lineage. Blood. 1999;94(2):411–6.PubMed

Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95(4):1443–50.PubMed

Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin’s and Reed–Sternberg cells. Am J Pathol. 1991;139(4):701–7.PubMedCentralPubMed

Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M, et al. Frequent expression of the B-cell-specific activator protein in Reed–Sternberg cells of classical Hodgkin’s disease provides further evidence for its B-cell origin. Blood. 1999;94(9):3108–13.PubMed

Schwarzer R, Dorken B, Jundt F. Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed–Sternberg cells. Leukemia. 2012;26(4):806–13. doi:10.1038/leu.2011.265.PubMedCrossRef

Re D, Muschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001;61(5):2080–4.PubMed

Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin’s disease. Am J Pathol. 2001;159(5):1807–14. doi:10.1016/S0002-9440(10)63027-1.PubMedCentralPubMedCrossRef

10.

Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7(2):207–15. doi:10.1038/ni1285.PubMedCrossRef

11.

Küppers R. New insights in the biology of Hodgkin lymphoma. ASH Educ Program Book. 2012;2012(1):328–34. doi:10.1182/asheducation-2012.1.328.

12.

Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221(3):248–63. doi:10.1002/path.2711.PubMedCrossRef

13.

Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812–26. doi:10.1200/JCO.2010.32.8401.PubMedCrossRef

14.

Armitage JO. Early-Stage Hodgkin’s Lymphoma. N Engl J Med. 2010;363(7):653–62. doi:10.1056/NEJMra1003733.PubMedCrossRef

15.

Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International prognostic score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30(27):3383–8. doi:10.1200/JCO.2011.41.0910.PubMedCrossRef

16.

Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252–9.PubMedCrossRef

17.

Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–12. doi:10.1056/NEJMoa1100340.PubMedCrossRef

18.

Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–84. doi:10.1056/NEJM199211193272102.PubMedCrossRef

19.

Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–91. doi:10.1200/JCO.2012.43.4803.PubMedCentralPubMedCrossRef

20.

Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208–17. doi:10.1182/blood-2010-09-288373.PubMedCrossRef

21.

Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146(2):158–63. doi:10.1111/j.1365-2141.2009.07727.x.PubMedCentralPubMedCrossRef

22.

Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2):310–7. doi:10.3324/haematol.2011.045757.

23.

von Wasielewski R, Mengel M, Fischer R, Hansmann ML, Hubner K, Franklin J, et al. Classical Hodgkin’s disease. Clinical impact of the immunophenotype. Am J Pathol. 1997;151(4):1123–30.

24.

Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, et al. Expression of the CD 30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190(5):613–8. doi:10.1002/(SICI)1096-9896(200004)190:5<613:AID-PATH559>3.0.CO;2-0.PubMedCrossRef

25.

Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, et al. CD 30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.PubMed

26.

Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD 30-mediated NFkappaB activation. J Biol Chem. 1997;272(4):2042–5.PubMedCrossRef

27.

Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene. 1998;17(25):3261–70. doi:10.1038/sj.onc.1202568.PubMedCrossRef

28.

Duckett CS, Thompson CB. CD 30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 1997;11(21):2810–21.PubMedCentralPubMedCrossRef

29.

Ho DS, REa AJ, Abraham LJ. Functional aspects of the CD 30 gene in Hodgkin’s lymphoma and anaplastic large cell lymphoma. Oncol Rev. 2009;3:89–101.CrossRef

30.

Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R, et al. CD 30-induced signaling is absent in Hodgkin’s cells but present in anaplastic large cell lymphoma cells. Am J Pathol. 2008;172(2):510–20. doi:10.2353/ajpath.2008.070858.PubMedCentralPubMedCrossRef

31.

Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD 30+ hematologic malignancies. Blood. 2008;111(4):1848–54. doi:10.1182/blood-2007-07-099317.PubMedCrossRef

32.

Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD 30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171–9. doi:10.1111/j.1365-2141.2009.07740.x.PubMedCrossRef

33.

Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II study of an anti-CD 30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764–9. doi:10.1200/JCO.2006.07.8972.PubMedCrossRef

34.

Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD 30 monoclonal antibody. J Clin Oncol. 2005;23(21):4669–78. doi:10.1200/JCO.2005.09.098.PubMedCrossRef

35.

Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD 30 immunotoxin. Lancet. 1992;339(8803):1195–6.PubMedCrossRef

36.

Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A phase I study with an anti-CD 30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD 30+ Hodgkin’s and non-Hodgkin’s lymphoma. Clin Cancer Res. 2002;8(6):1779–86.PubMed

37.

Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, et al. Anti-CD16/CD 30 bispecific antibody treatment for Hodgkin’s disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res. 2001;7(7):1873–81.PubMed

38.

Brentuximab vedotin. Drugs R D. 2011;11(1):85–95. doi:10.2165/11591070-000000000-00000.

39.

Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD 30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt 1):843–52.PubMed

40.

Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990;39(12):1941–9.PubMedCrossRef

41.

Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, et al. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005;23(3):257–61. doi:10.1007/s10637-005-6735-y.PubMedCrossRef

42.

von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, et al. Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. Sarcoma. 2004;8(4):107–11. doi:10.1080/13577140400009163.CrossRef

43.

Saad ED, Kraut EH, Hoff PM, Moore DF Jr, Jones D, Pazdur R, et al. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol. 2002;25(5):451–3.PubMedCrossRef

44.

Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7. doi:10.1038/nbt.2289.PubMedCrossRef

45.

Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–84. doi:10.1038/nbt832.PubMedCrossRef

46.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD 30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65. doi:10.1182/blood-2003-01-0039.PubMedCrossRef

47.

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD 30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21. doi:10.1056/NEJMoa1002965.PubMedCrossRef

48.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. doi:10.1200/jco.2011.38.0410.PubMedCentralPubMedCrossRef

49.

Bartlett N, Brice P, Chen RW, Fanale MA, Gopal AK, Matous J, et al. Retreatment with brentuximab vedotin in CD 30-positive hematologic malignancies: a phase II study. ASCO Meeting Abstr. 2012;30((15_suppl)):8027.

50.

Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–81. doi:10.1182/blood-2012-03-418673.PubMedCentralPubMedCrossRef

51.

Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD 30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98(4):611–4. doi:10.3324/haematol.2012.069393.PubMedCentralPubMedCrossRef

52.

Gopal AK, Ramchandren R, O’Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–8. doi:10.1182/blood-2011-12-397893.PubMedCentralPubMedCrossRef

53.

van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4(4):458–65. doi:10.4161/mabs.20230.PubMedCentralPubMedCrossRef

54.

Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, et al. Persistence of CD 30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma. 2012;53(10):2051–3. doi:10.3109/10428194.2012.666543.PubMedCrossRef

55.

Ansell SM, Connors JM, Park SI, O’Meara MM, Younes A. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. ASH Annu Meeting Abstr. 2012;120(21):798.

Title: Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin
Authors: Matthew Mei
Sandra Thomas
Robert Chen
Publication date: 01-06-2014
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 3/2014
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-013-0077-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Safety and Pharmacokinetics of Escalating Doses of Human Recombinant Nerve Growth Factor Eye Drops in a Double-Masked, Randomized Clinical Trial

Bacteriophage Polysaccharide Depolymerases and Biomedical Applications

A Review of CT-P13: An Infliximab Biosimilar

Attenuation of Carbon Tetrachloride-Induced Hepatic Injury with Curcumin-Loaded Solid Lipid Nanoparticles

Erratum to: Bacteriophage Polysaccharide Depolymerases and Biomedical Applications

Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)